{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:35:49Z","timestamp":1789529749575,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1124\/dmd.118.086074","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T21:49:17Z","timestamp":1551736157000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites"],"prefix":"10.1016","volume":"47","author":[{"given":"Yuli","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.086074_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/dmd.112.047878","article-title":"Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse","volume":"41","author":"Al Saabi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jinorgbio.2018.03.016","article-title":"Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2","volume":"184","author":"Arnold","year":"2018","journal-title":"J Inorg Biochem"},{"key":"10.1124\/dmd.118.086074_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","article-title":"CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin","volume":"70","author":"Bland","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.086074_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1124\/dmd.118.086074_bib5","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P&T"},{"key":"10.1124\/dmd.118.086074_bib6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jat\/10.4.129","article-title":"Tetrahydrocannabinol stability in whole blood: plastic versus glass containers","volume":"10","author":"Christophersen","year":"1986","journal-title":"J Anal Toxicol"},{"key":"10.1124\/dmd.118.086074_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1373\/clinchem.2013.216507","article-title":"Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis","volume":"60","author":"Desrosiers","year":"2014","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.118.086074_bib9","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1124\/dmd.118.086074_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.forsciint.2012.08.013","article-title":"Distribution of free and conjugated cannabinoids in human bile samples","volume":"223","author":"Fabritius","year":"2012","journal-title":"Forensic Sci Int"},{"key":"10.1124\/dmd.118.086074_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1124\/dmd.118.086074_bib12","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1124\/dmd.110.034454","article-title":"In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities","volume":"38","author":"Fukami","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jps.2600630705","article-title":"Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol","volume":"63","author":"Garrett","year":"1974","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.086074_bib14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.118.086074_bib15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.118.086074_bib16","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.forsciint.2011.04.010","article-title":"A preliminary investigation on the distribution of cannabinoids in man","volume":"210","author":"Gronewold","year":"2011","journal-title":"Forensic Sci Int"},{"key":"10.1124\/dmd.118.086074_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.086074_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.086074_bib19","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1128\/AAC.01541-08","article-title":"Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system","volume":"53","author":"Hoffmann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.118.086074_bib20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem Biodivers"},{"key":"10.1124\/dmd.118.086074_bib21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jat\/16.5.276","article-title":"Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana","volume":"16","author":"Huestis","year":"1992","journal-title":"J Anal Toxicol"},{"key":"10.1124\/dmd.118.086074_bib22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.086074_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/bms.1200140904","article-title":"Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking","volume":"14","author":"Johansson","year":"1987","journal-title":"Biomed Environ Mass Spectrom"},{"key":"10.1124\/dmd.118.086074_bib25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600681106","article-title":"Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol","volume":"68","author":"Jusko","year":"1979","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.086074_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt1978244406","article-title":"Enhanced biotransformation of theophylline in marihuana and tobacco smokers","volume":"24","author":"Jusko","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.086074_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00002030-200203080-00005","article-title":"The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir","volume":"16","author":"Kosel","year":"2002","journal-title":"AIDS"},{"key":"10.1124\/dmd.118.086074_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.118.086074_bib29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jat\/bkv082","article-title":"Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users","volume":"39","author":"Lee","year":"2015","journal-title":"J Anal Toxicol"},{"key":"10.1124\/dmd.118.086074_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"key":"10.1124\/dmd.118.086074_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF00427095","article-title":"Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis","volume":"74","author":"Lindgren","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.118.086074_bib32","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.086074_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","article-title":"Potency trends of \u03949-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008","volume":"55","author":"Mehmedic","year":"2010","journal-title":"J Forensic Sci"},{"key":"10.1124\/dmd.118.086074_bib34","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and glucuronide whole blood cannabinoids\u2019 pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.118.086074_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed Environ Mass Spectrom"},{"key":"10.1124\/dmd.118.086074_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/clpt.1982.86","article-title":"Comparison of effects of marihuana cigarettes to three different potencies","volume":"31","author":"Perez-Reyes","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.086074_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11095-011-0637-9","article-title":"Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions","volume":"29","author":"Rhoades","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.086074_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jbt.20178","article-title":"Human carboxylesterases and their role in xenobiotic and endobiotic metabolism","volume":"21","author":"Ross","year":"2007","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.118.086074_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1165\/ajrcmb.24.3.4252","article-title":"Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol","volume":"24","author":"Roth","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/dmd.118.086074_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.118.086074_bib41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/dmd.30.5.488","article-title":"Current progress on esterases: from molecular structure to function","volume":"30","author":"Satoh","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib42","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1373\/clinchem.2011.171777","article-title":"Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration","volume":"57","author":"Schwope","year":"2011","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.118.086074_bib43","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems","author":"Segel","year":"1975"},{"key":"10.1124\/dmd.118.086074_bib44","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1248\/bpb.20.869","article-title":"Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver","volume":"20","author":"Takai","year":"1997","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.118.086074_bib45","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1124\/dmd.118.086074_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fitote.2017.01.010","article-title":"Recent progress in the discovery of natural inhibitors against human carboxylesterases","volume":"117","author":"Wang","year":"2017","journal-title":"Fitoterapia"},{"key":"10.1124\/dmd.118.086074_bib48","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci"},{"key":"10.1124\/dmd.118.086074_bib50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2133\/dmpk.DMPK-11-RG-107","article-title":"Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity","volume":"27","author":"Yamaori","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.086074_bib51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.086074_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11419-011-0112-7","article-title":"Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids","volume":"29","author":"Yamaori","year":"2011","journal-title":"Forensic Toxicol"},{"key":"10.1124\/dmd.118.086074_bib53","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.111.041384","article-title":"Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6","volume":"39","author":"Yamaori","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.086074_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","article-title":"Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions","volume":"270","author":"Zhu","year":"2010","journal-title":"Toxicology"},{"key":"10.1124\/dmd.118.086074_bib55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","article-title":"Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis","volume":"82","author":"Zhu","year":"2008","journal-title":"Am J Hum Genet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.086074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:44Z","timestamp":1739957024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0090955624078139"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.086074","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.086074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}